As cancer research scientists continue to explore vaccines as a way to treat cancer, we will continue to inform you about new experimental mesothelioma vaccine clinical trials recruiting volunteers. The mesothelioma clinical trial we report on here is intriguing because it is a pilot study. That means it is so experimental that it is a small preliminary study to help researchers get enough information to design a full-scale research project. Because it is a pilot study, it is being conducted by the National Cancer Institute only at the National Institutes of Health’s Clinical Center in Bethesda, Maryland which is a suburb of Washington D.C. So if you like the idea of going to Washington once a month for six months, then every three months for the next two years and then every six months for three years after that, this might be a clinical trial you might consider. But check with your oncologist first.
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
ClinicalTrials.gov Identifier NCT01143545
First received June 11, 2010
Last Updated May 3, 2014
Sponsor National Cancer Institute
Purpose Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces. Research studies have shown that giving a vaccine that contains antigens similar to these may cause an immune response, which may keep tumors from growing. Researchers are also interested in determining whether the chemotherapy drug cyclophosphamide and the anti-inflammatory drug celecoxib may help the vaccine work better.
Discussion of Outcome Measures Evaluate the safety and effectiveness of tumor cell vaccines in combination with cyclophosphamide and celecoxib in patients with cancers involving the chest.
Estimated Enrollment 25
Study Start Date May 2010
Estimated Study Completion Date May 2017
Eligibility Life expectancy of more than 12months, evidence of adequate bone marrow reserve, no hypertension or heart disease. For complete list, see study webpage.
Contacts and Locations
|Tricia Kunst, R.N.||(301) firstname.lastname@example.org|
|David S. Schrump M.D. (301) email@example.com|
National Institutes of Health Clinical Center
9000 Rockville Pike
Bethesda, MD 20892